How much is the latest price of a box of tucatinib/tucatinib?

Tucatinib/Tucatinib (Tucatinib) is a targeted therapy drug mainly used to treat patients with HER2-positive breast cancer, especially those who have received other treatments but still progressed. Its mechanism of action is mainly by selectively inhibiting the activity ofHER2 tyrosine kinase, thereby preventing the growth and spread of tumor cells. Tucatinib is often used in combination with other anti-cancer drugs to enhance the therapeutic effect, especially when combined with trastuzumab and chemotherapy drugs, it can significantly improve patient prognosis.

In terms of clinical application, tucatinib has shown good efficacy. Multiple clinical trials have shown that it can effectively control disease progression and improve patients’ progression-free survival (PFS). Additionally, the relatively low incidence of side effects makes it a safe treatment option. According to the latest clinical data, tucatinib can still provide new hope for patients after previous treatment, especially in patients with metastatic breast cancer.

However, because the original drug of tucatinib has not yet been launched in China, it is not currently included in the medical insurance system, which makes patients face a high financial burden. In overseas markets, especially in Europe, the price of tucatinib is relatively high. Each box of 150 mg usually sells for more than 40,000 yuan, which is a heavy expense for many patients.

Fortunately, with the development of the global pharmaceutical industry, generic drugs of tucatinib have also become available. For example, the market price of a 150mg generic drug produced by a Lao pharmaceutical factory is about RMB 2,000, which greatly reduces the financial pressure on patients. These generic drugs are almost identical in composition and efficacy to the original drugs, ensuring their safety and effectiveness when used by patients.

Reference materials:https://www.tukysa.com/